Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation boost may extend lives in advanced liver cancer

NCT ID NCT07274774

Disease control Sponsor: Shandong Cancer Hospital and Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two treatments for advanced liver cancer (BCLC stage C): standard drug therapy alone versus drug therapy plus a precise type of radiation called stereotactic body radiotherapy (SBRT). The goal is to see if adding radiation helps people live longer. About 184 adults aged 18-70 with good liver function will take part. The study is currently recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 184 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-70 years. 2. Histologically or clinically diagnosed HCC per national guidelines. 3. BCLC stage C (CNLC IIIA/IIIB), including PVTT and/or extrahepatic metastases amenable to protocol procedures. 4. Child-Pugh class A or B (score ≤7). 5. At least one measurable lesion per RECIST 1.1 (criteria specified). 6. ECOG ≤2. 7. Expected survival ≥6 months. 8. Adequate organ function per protocol thresholds. 9. For experimental arm candidates: active lesion count (when PET-CT used) ≤10. 10. If prior initial systemic therapy given: intrahepatic disease stable ≥3 months. 11. Effective contraception from consent through 1 year after treatment end. 12. Ability to understand and sign consent. Exclusion Criteria: 1. Second primary malignancy (exceptions apply). 2. Tumor thrombus/metastases judged not amenable to radiotherapy. 3. Prior systemic anticancer therapy for current HCC (prior local therapy permitted per rules). 4. Severe organ dysfunction precluding treatment. 5. Uncontrolled comorbidities (e.g., uncontrolled diabetes, active peptic ulcer, severe cardiopulmonary disease). 6. Active uncontrolled infection or active autoimmune disease requiring systemic therapy. 7. Significant neurologic dysfunction. 8. Pregnant or breastfeeding women; no effective contraception. 9. Known hypersensitivity to planned drugs. 10. Any other condition making participation unsuitable per investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCLC stage C hepatocellular carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BCLC stage C hepatocellular carcinoma Hepatocellular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shandong Cancer Hospital and Institute

    RECRUITING

    Jinan, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.